A new vaccine to protect against dengue virus infections
Dengue virus mRNA lipid nanoparticle vaccine
This study is testing a new mRNA vaccine for dengue that aims to help your body fight off all four types of the virus safely, and if you have dengue, you might have a chance to participate in trials to see how well it works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10885083 on NIH RePORTER |
What this research studies
This research focuses on developing a novel vaccine for dengue virus using mRNA technology encapsulated in lipid nanoparticles. The approach aims to stimulate a strong immune response that can effectively target all four serotypes of the dengue virus, which is crucial for preventing severe disease. By utilizing a non-infectious platform, the vaccine seeks to avoid complications associated with existing vaccines. Patients may be involved in trials to assess the safety and efficacy of this innovative vaccine.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living in tropical and subtropical regions who are at risk of dengue virus infection.
Not a fit: Patients who have already been vaccinated with Dengvaxia or those not residing in dengue-endemic areas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safe and effective vaccine to protect millions from dengue virus infections and their severe complications.
How similar studies have performed: Other mRNA vaccine approaches have shown promise in combating various infectious diseases, indicating potential for success in this novel application.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Richner, Justin — University of Illinois at Chicago
- Study coordinator: Richner, Justin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.